Talecris Biotherapeutics Holdings Corp. (NASDAQ: TLCR) has appointed Dean Jonathan Mitchell to its Board of Directors. The appointment brings the number of members on the board to 10. Mitchell is a pharmaceuticals executive with a record of building businesses and creating value for shareholders. His experience includes commercial management, clinical development, global product launches, executive management and strategic acquisitions. He has held leadership positions at companies such as Alpharma Inc., Guilford Pharmaceuticals, Inc., Bristol-Myers Squibb and GlaxoSmithKline.
Penny Stock Professor, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Penny Stock Picks.
About Talecris Biotherapeutics
Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology and hemostasis.
Follow us on Twitter: http://www.twitter.com/pennystockspro
Sign up for the free Penny Stock Professor newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Us
Penny Stock Professor is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
